Since the mid-1980s, therapeutic monoclonal antibodies have become the fastest-growing class of therapeutics. This was due to the numerous pharmaceutical companies that were trying to find more drug ...

First in human (FIH) clinical trials of bispecific immunostimulatory antibodies commonly require a low starting dose based on a minimum anticipated biological effect level (MABEL) approach. To ...

As the use of immunoassays to discover, detect, and quantitate proteins from a variety of biological samples has greatly expanded, so have requirements for enhanced sensitivity, precision, reliability ...

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, has published new findings on the generation and characterization of drug-target complex-specific ...

Drug safety and efficacy are key concerns for manufacturers during the long, complex, and costly drug development process. Regulatory agencies now expect that immune responses caused by drug treatment ...

As scientists continue to expand the utility of biomarkers in basic and applied life science research, advances in immunoassay technologies further empower these efforts by improving the way key ...

Having a robust immunogenicity assay for accurate evaluation of ADA in animal models is important for enabling effective decision-making during development. Learn how a robust anti-drug antibody assay ...

HERCULES, Calif., April 21, 2020 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, has extended its range of recombinant ...

In writing about what attributes and skills qualify a scientist for a successful career in assay development for drug discovery, one characteristic that rarely gets discussed — but which is essential ...